Survodutide

Basic Introduction

Survodutide is a novel, long‑acting dual‑agonist peptide compound that simultaneously targets GLP‑1 (Glucagon‑Like Peptide‑1) and GIP (Glucose‑Dependent Insulinotropic Polypeptide) receptors. It belongs to the next‑generation weight‑management and metabolic health peptide family, more potent and longer‑lasting than Tirzepatide, Semaglutide, and Retatrutide.

Developed for research‑grade metabolic regulation, body composition optimization, and anti‑obesity therapy, Survodutide delivers superior fat loss, appetite suppression, insulin‑sensitizing, and anti‑inflammatory effects. It is a high‑end research peptide offered by Slimbiotech and SSR Biotechnology, widely used in advanced weight‑loss and longevity research programs.

Core Mechanism

Survodutide activates both GLP‑1 and GIP receptors in the brain and gastrointestinal tract. It suppresses central appetite signals, slows gastric emptying, reduces calorie intake, enhances insulin secretion, improves insulin sensitivity, boosts fat oxidation, and regulates liver and adipose tissue metabolism. Its long half‑life allows once‑weekly administration for steady, sustained metabolic control.

Key Functions & Core Benefits

1. Powerful Appetite Suppression & Rapid Weight Loss

   Strongly reduces hunger, cravings, and emotional eating; lowers total daily calorie intake; promotes significant reduction in overall body weight, visceral fat, and stubborn belly fat; achieves more robust fat‑loss results than traditional single‑target GLP‑1 peptides.

2. Improve Insulin Sensitivity & Regulate Blood Glucose

   Enhances glucose uptake and utilization in cells; stabilizes blood sugar levels; improves insulin resistance; supports metabolic health for pre‑diabetic and metabolic‑syndrome populations.

3. Optimize Body Composition & Reduce Adipose Tissue

   Targets harmful visceral fat specifically; preserves lean muscle mass during fat‑loss cycles; improves fat‑to‑muscle ratio; synergizes with AICAR, L‑Carnitine, and MK‑677 for advanced body‑recomposition outcomes.

4. Long‑Term Metabolic Anti‑Aging Effect

   Reduces chronic low‑grade inflammation linked to obesity and aging; lowers oxidative stress; improves cardiovascular risk factors such as triglycerides and blood pressure; supports longevity when combined with FOXO4‑DRI senolytic peptide.

5. Liver Health Protection

   Reduces liver fat accumulation; improves non‑alcoholic fatty liver conditions; enhances hepatic metabolic function.

6. Convenient Long‑Acting Administration

   Long half‑life enables once‑weekly dosing, providing steady 24‑7 day appetite and metabolic control without daily injections.

Standard Usage Protocol

• Dosage: 2–10 mg per vial; reconstitute with Sterile Water for Injection (3 mL)
• Injection Dose: Start with 0.25 mg weekly, titrate gradually up to 1–2 mg weekly
• Frequency: Once weekly, subcutaneous injection
• Cycle: 12–24 weeks for full weight‑loss and metabolic optimization research program
• Note: For research use only, not approved for human clinical treatment.

Product Position

Survodutide is a cutting‑edge dual‑receptor agonist peptide supplied by SSR Biotechnology & Slimbiotech, applied in global advanced weight‑loss research labs, metabolic health clinics, anti‑aging longevity programs, and high‑grade peptide body‑recomposition stacks.

Research Use Only. This catalog information is reproduced from the customer legacy website. Products are not for human or veterinary use. Confirm current specification, availability and documentation before ordering.